Search results
Results from the WOW.Com Content Network
Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. [2] Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion .
Depending on the person, the cancer, the stage of cancer, the type of chemotherapy, and the dosage, intravenous chemotherapy may be given on either an inpatient or an outpatient basis. For continuous, frequent or prolonged intravenous chemotherapy administration, various systems may be surgically inserted into the vasculature to maintain access.
It generally affects about 10–40% of breast cancer patients, with higher rates among pre-menopausal women and patients who receive high-dose chemotherapy. [4] Additionally, there are high complaints of cognitive impairment in glioblastoma patients; 60–85% of patients report cancer-related cognitive impairments following surgery and ...
The Mayo Clinic Cancer Center is one of the oldest NCI-designated cancer centers in the United States, having first been designated in 1973. [3] The main location of the Mayo Clinic is in Rochester, MN. Campuses in Arizona and Florida opened later and became part of the Mayo Clinic Cancer Center in 2003. [4] [5]
Cancer treatments are a wide range of treatments available for the many different types of cancer, with each cancer type needing its own specific treatment. [1] Treatments can include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy including small-molecule drugs or monoclonal antibodies, [2] and PARP inhibitors such as olaparib. [3]
Cetuximab is the first-line therapy for Ménétrier disease. [2] Cetuximab is a monoclonal antibody against epidermal growth factor receptor (EGFR), and has been shown to be effective in treating Ménétrier disease. [7] Several medications have been used in the treatment of the condition, with variable efficacy.
With competent management, cancer pain can be eliminated or well controlled in 80% to 90% of cases, but nearly 50% of cancer patients in the developed world receive less than optimal care. Worldwide, nearly 80% of people with cancer receive little or no pain medication. [4]
Low-dose chemotherapy is being studied/used in the treatment of cancer to avoid the side effects of conventional chemotherapy. Historically, oncologists have used the highest possible dose that the body can tolerate in order to kill as many cancer cells as possible. [1] After high-dose treatments, the body reacts, sometimes quite severely.